## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 1.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($69.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Henry Schein Expands Partnership with vVARDIS**
- Source: Yahoo Finance | 20251201T213400 | Bullish | Relevance: 99%
- Henry Schein, Inc. announced an expanded exclusive U.S. distribution agreement with vVARDIS for its Curodont™ Repair Fluoride Plus product, effective January 1, 2026. This partnership will extend the drill-free cavity treatment to all dental market segments, including general dentistry, orthodontics, and pediatric dentistry nationwide. The expansion follows successful prior collaboration, with Curodont™ already reaching over 10% of U.S. dental offices and treating more than 500,000 patients.

**2. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com Nigeria | 20251201T224600 | Bullish | Relevance: 99%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, to cover all dental market segments starting January 1, 2026. This expansion builds on a successful prior partnership and aims to reach broader dental practices and address the high prevalence of early-stage cavities. The announcement follows Henry Schein's strong third-quarter 2025 earnings, which surpassed analyst expectations.

**3. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com | 20251201T164500 | Bullish | Relevance: 98%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, to include all dental market segments starting January 1, 2026. This expansion broadens their previous 2024 agreement which was limited to Dental Service Organizations, now extending to general dentistry, orthodontics, and pediatric dentistry nationwide. The move reflects Henry Schein's strengthening position in the dental supplies market and vVARDIS's success with the product, which has already been adopted by over 10% of U.S. dental offices.

**4. Henry Schein (Nasdaq: HSIC) to be exclusive US Curodont distributor across dental market**
- Source: Stock Titan | 20251201T213400 | Bullish | Relevance: 98%
- Henry Schein, Inc. has expanded its partnership with vVARDIS, gaining exclusive U.S. distribution rights for the Curodont™ Repair Fluoride Plus product across all dental market segments, effective January 1, 2026. This expansion builds on a previous agreement for Dental Service Organizations and will now cover general dentistry, orthodontics, and pediatric dentistry nationwide. Curodont™ is a drill-free, needle-free solution for early-stage cavities, addressing a significant unmet need in oral health.

**5. Henry Schein expands vVARDIS distribution deal for drill-free cavity treatment**
- Source: Investing.com UK | 20251201T214600 | Bullish | Relevance: 98%
- Henry Schein, Inc. has expanded its exclusive U.S. distribution agreement with vVARDIS for Curodont Repair Fluoride Plus, a drill-free cavity treatment, to include all dental market segments starting January 1, 2026. This expansion builds on a previous agreement limited to Dental Service Organizations, extending the product's reach to general dentistry, orthodontics, and pediatric dentistry nationwide. The healthcare distributor, which has a market capitalization of $8.61 billion and annual revenue of $12.94 billion, announced this expansion following a strong third-quarter 2025 earnings report.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 7.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 13.8 |
| Current P/E | 14.9 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.5% to -2.0% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Underperforming sector by 3.4pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.05% (CS: 26) | Weak |
| RSI_14 | 58.9 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.080x | Above |
| vs SMA200 | 1.055x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $73.11
- **Stop Loss:** $69.73 (4.6% risk)
- **Target:** $76.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 221
- **Position Value:** $16,157.31
- **Portfolio %:** 16.16%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*